| Date | Title | Description |
| 07.07.2026 | Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 02.06.2026 | Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases | Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases
Civorebrutinib adds pipeline-in-a-product potential across m... |
| 10.10.2025 | Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan | TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (deve... |
| 26.09.2025 | CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX... |
| 29.04.2025 | CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN)
Decision follows positive recommendation from Committee for Medicinal Products for ... |
| 17.03.2025 | Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS | sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS
If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney f... |
| 17.03.2025 | Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS | sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS
If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney f... |
| 12.03.2025 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 7... |
| 12.02.2025 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of... |
| 11.02.2025 | Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS | Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and lea... |
| 11.02.2025 | Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS | Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and lea... |
| 13.01.2025 | Travere Therapeutics Provides Corporate Update and 2025 Outlook | Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter
sNDA requesting modification of liver monitoring fo... |
| 06.01.2025 | Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesd... |
| 25.11.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
7th Annual Evercore HealthCONx Conferen... |
| 25.11.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
7th Annual Evercore HealthCONx Conferen... |
| 13.11.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, c... |
| 04.11.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November:
Guggenheim Securities Healthcare Innova... |
| 31.10.2024 | Travere Therapeutics Reports Third Quarter 2024 Financial Results | FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN
Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FS... |
| 26.10.2024 | Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 | Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment
SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and ... |
| 26.10.2024 | Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 | Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment
SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and ... |
| 21.10.2024 | Travere Therapeutics to Report Third Quarter 2024 Financial Results | SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Com... |
| 21.10.2024 | Travere Therapeutics to Report Third Quarter 2024 Financial Results | SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Com... |
| 17.10.2024 | CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial
ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeuti... |
| 17.10.2024 | Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy | SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA ne... |
| 14.10.2024 | Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 | Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies
Late-breaking presentation det... |
| 14.10.2024 | Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 | Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies
Late-breaking presentation det... |
| 26.09.2024 | Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up | SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HC... |
| 12.09.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees,... |
| 10.09.2024 | Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference | SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.
A... |
| 05.09.2024 | Raising Awareness and Empowering Patients: The Fight Against Kidney Disease | Kidney disease is a silent predator. It lurks in the shadows, often unnoticed until it strikes. The statistics are alarming. Approximately 35.5 million adults in the U.S. have chronic kidney disease (CKD), yet around 90% are unaware of thei... |
| 05.09.2024 | Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy | FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that ac... |
| 03.09.2024 | NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024 | PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on Sep... |
| 22.08.2024 | Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 | Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (N... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 06.08.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:
2024 Wedbush PacGrow Healthcare Conferenc... |
| 06.08.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:
2024 Wedbush PacGrow Healthcare Conferenc... |
| 01.08.2024 | Travere Therapeutics Reports Second Quarter 2024 Financial Results | Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch
Net product sales of FILSPARI totaled $27.1 million fo... |
| 25.07.2024 | Travere Therapeutics to Report Second Quarter 2024 Financial Results | SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. financial markets. The Com... |
| 08.07.2024 | BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial | SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-bli... |
| 08.07.2024 | Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference | SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m.... |
| 11.06.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, con... |
| 15.05.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,50... |
| 29.04.2024 | Travere Therapeutics to Report First Quarter 2024 Financial Results | SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets. The C... |
| 24.04.2024 | CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial
... |
| 04.04.2024 | Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International | Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVT... |
| 13.03.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 13.03.2024 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 5... |
| 26.02.2024 | Travere Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:
Cowen 44th Annual Health Care Conferenc... |
| 15.02.2024 | Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results | Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023
Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval
CHMP opinio... |
| 01.02.2024 | Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference | SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. E... |
| 08.01.2024 | Travere Therapeutics Provides Corporate Update and 2024 Outlook | Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter
Company on track to submit sNDA to FDA in Q1 2024 for conver... |
| 21.11.2023 | Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference | SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.... |
| 20.07.2023 | Travere Therapeutics to Report Second Quarter 2023 Financial Results | /EIN News/ -- SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial mar... |
| 27.06.2023 | Rare Disease Patient Advocates Gather in San Diego for a Week of Events to Connect, Learn, and Empower | Week in RARE events "We are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease d... |
| 08.06.2023 | Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 | /EIN News/ -- SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3... |
| 04.05.2023 | Travere Therapeutics Reports First Quarter 2023 Financial Results | /EIN News/ -- FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17th, 2023; commercial launch underway
Total net product sales of $50.3 million for the first qua... |
| 02.05.2023 | Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test | When Travere Therapeutics initially fell short of providing sufficient clinical data to support an application seeking accelerated drug approval in a rare kidney disorder, the FDA told the biotech last year that carrying out a Phase 3 study... |
| 01.05.2023 | Travere Therapeutics drug, approved for one rare and deadly kidney disease, fails in study of another | SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a rare and deadly kidney disease, failed to improve... |
| 01.04.2023 | Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 | SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. TVTX today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT Study evaluating FILSPARI™... |
| 01.04.2023 | Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 | FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control
/EIN News/ -- SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announ... |
| 22.02.2023 | FDA Approval of Travere Kidney Disease Drug Sets Up Blockbuster Expectations | Travere Therapeutics has won FDA approval for a drug that treats a rare autoimmune disorder that is typically first noticed as blood in the urine and can progress over time to end-stage kidney failure.
The regulatory decision for Travere’s ... |
| 27.10.2022 | Travere Therapeutics Reports Third Quarter 2022 Financial Results | EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023
New PDUFA target action date for sparsentan in IgAN set for February 17, 2023
Net... |
| 07.09.2021 | Vaccitech makes short move to new headquarters; EnteroBiotix raises more than $21M in Series A | Oxford biotech Vaccitech is moving headquarters — but only about 20 minutes away.
Vaccitech signed a lease for 31,000 square feet within the Zeus development at Harwell Science and Innovation Campus. The firm plans to rel... |
